Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C2 | P08235 | 1/20 | 0.47 |
| ▸ | GRM5 | P41594 | 1/20 | 0.42 |
| ▸ | MMP12 | P39900 | 1/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | RAF1 | P04049 | 1/20 | 0.34 |
| ▸ | BRAF | P15056 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | FAAH | O00519 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16746129 | 0.79 | MMP12 (0.43) | NR3C2GRM5MMP12TRPV1PARP1 | |
| SCHEMBL17344745 | 0.79 | NR3C2 (0.52) | NR3C2GRM5MMP12TRPV1PARP1 | |
| SCHEMBL3488166 | 0.78 | NR3C2 (0.54) | NR3C2GRM5MMP12PARP1SMN1; SMN2 | |
| SCHEMBL11003940 | 0.78 | GRM5 (0.41) | NR3C2GRM5MMP12PARP1ADRB1 | |
| SCHEMBL71434 | 0.76 | GABRA1 (0.38) | TRPV1LMNAFAAHCA1CA2 | |
| SCHEMBL2611032 | 0.75 | AHR (0.56) | GRM5TRPV1LMNAFAAHCA1 | |
| SCHEMBL2483112 | 0.75 | NR3C2 (0.47) | NR3C2GRM5MMP12PARP1SMN1; SMN2 | |
| SCHEMBL30609076 | 0.75 | NR3C2 (0.47) | NR3C2GRM5MMP12TRPV1PARP1 | |
| SCHEMBL1137855 | 0.75 | GRM5 (0.48) | NR3C2GRM5MMP12PARP1ADRB1 | |
| SCHEMBL3489518 | 0.75 | NR3C2 (0.47) | NR3C2GRM5MMP12PARP1CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024108155-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS | DENALI THERAPEUTICS INC. (US) | 2024-05-23 | — | — | WO | disclosed |
| US-11820768-B2 | 4-azaindole compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-11-21 | — | — | US | disclosed |
| US-11820766-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-21 | — | — | US | disclosed |
| US-20230295122-A1 | 1H-BENZO[D]IMIDAZOLE DERIVATIVES AS TLR9 INHIBITORS FOR THE TREATMENT OF FIBROSIS | BRISTOL MYERS SQUIBB CO (US) | 2023-09-21 | — | — | US | disclosed |
| WO-2020065613-A1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-04-02 | — | — | WO | disclosed |
| US-20180079727-A1 | 9-MEMBERED FUSED RING DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2018-03-22 | — | — | US | disclosed |
| US-20160257641-A1 | NOVEL ALKYLENE DERIVATIVES | SHIONOGI & CO., LTD. (JP) | 2016-09-08 | — | — | US | disclosed |
| EP-0548254-B1 | 6- OR 7-(IMIDAZOLIDIN-2-YLIDENEAMINO)-1,4-BENZOXAZINES AS ALPHA ADRENERGIC AGENTS | ALLERGAN INC (US) | 1999-06-02 | — | — | EP | disclosed |
| EP-0548254-A1 | 6- or 7- (2-IMINO-2-IMIDAZOLIDINE)-1,4-BENZOXAZINES AS ALPHA ADRENERGIC AGENTS | ALLERGAN, INC. (US) | 1993-06-30 | — | — | EP | disclosed |
| WO-1992004345-A1 | 6- or 7- (2-IMINO-2-IMIDAZOLIDINE)-1,4-BENZOXAZINES AS ALPHA ADRENERGIC AGENTS | ALLERGAN, INC. (US) | 1992-03-19 | — | — | WO | disclosed |
| US-5091528-A | Antiglaucoma, antidiarrhea agents, diuretics, vasoconstrictors | ALLERGAN, INC. (US) | 1992-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11820768-B2 | 4-azaindole compounds | TLR7, TLR9, TLR5 | NR3C2 286/4885GRM5 58/4885MMP12 2521/4885 |
| US-20180079727-A1 | 9-MEMBERED FUSED RING DERIVATIVE | ACSS2, AGTR2, ACSL3 | NR3C2 155/4885GRM5 3770/4885MMP12 3775/4885 |
| US-20230295122-A1 | 1H-BENZO[D]IMIDAZOLE DERIVATIVES AS TLR9 INHIBITORS FOR THE TREATMENT OF FIBROSIS | TLR9, TLR1, TLR7 | NR3C2 1494/4885GRM5 3423/4885MMP12 939/4885 |
| US-20160257641-A1 | NOVEL ALKYLENE DERIVATIVES | ACSS2, ACACB, ADCY2 | NR3C2 267/4885GRM5 3101/4885MMP12 3856/4885 |
| US-11820766-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, PNLIP | NR3C2 1892/4885GRM5 153/4885MMP12 2522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.